1. Clinical & Scientific Overview
Artemether + Lumefantrine & Artesunate (TIP-MED-000158, Reference Code [8.30]) is classified under
Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08) as a Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.30], p. 107): Artemether + Lumefantrine (ACT-AL): Falcigo-LF, Coartem (Novartis), Lumax, Lumerax (Ipca). Parenteral Artesunate: Falcigo (Zydus), Larinate (Ipca) — Strengths & Dosage Forms: ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM
ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM
3. Mechanism of Action & Pharmacodynamics
Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08): clinical efficacy is mediated via Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022) for ACT-AL: First-line oral treatment for uncomplicated Plasmodium falciparum malaria (and mixed infections) across India. Parenteral Artesunate: First-line life-saving emergency treatment for Severe / Cerebral Malaria!.
4. Therapeutic Indications & Evidence-Supported Uses
- ACT-AL: First-line oral treatment for uncomplicated Plasmodium falciparum malaria (and mixed infections) across India
- Parenteral Artesunate: First-line life-saving emergency treatment for Severe / Cerebral Malaria!
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: ACT-AL Adult (>=35 kg) 6-DOSE, 3-DAY REGIMEN: 80/480 mg (1 Adult Forte tablet, or 4 standard 20/120 mg tablets) at 0 Hours, 8 Hours (on Day 1), then at 24h, 36h, 48h, and 60h (Twice Daily on Days 2 & 3) — Total 6 Doses over 3 Days (+ Single-dose Primaquine 45 mg on Day 2!). Severe Malaria (IV Artesunate): 2.4 mg/kg IV/IM at 0h, 12h, and 24h, then once daily
Administration & Meal Timing: MANDATORY FAT/MILK ABSORPTION RULE FOR LUMEFANTRINE: Every dose of Artemether + Lumefantrine MUST be taken WITH FOOD OR A GLASS OF MILK! Without dietary fat, Lumefantrine oral absorption drops by 90% and malaria treatment fails! | Day 1: Hour 0 & Hour 8; Days 2 & 3: Morning & Evening (12-hourly) WITH MILK OR FOOD
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!
Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!
Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in congenital QTc prolongation, hypokalaemia/hypomagnesaemia, and concomitant strong CYP3A4 inducers (Rifampicin, Carbamazepine, Phenytoin). WHO guidelines endorse Artemether-Lumefantrine across all trimesters of pregnancy!
Key Clinical Precautions: Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!
8. Adverse Effects Profile
- Headache, dizziness, anorexia, nausea, arthralgia/myalgia, fatigue, mild QTc prolongation
- Treatment failure/recrudescence if taken on an empty stomach without fat/milk; Post-Artesunate Delayed Haemolysis (PADH — check Hb at Days 7, 14, 21, & 28 after IV Artesunate!); QTc prolongation
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Strong CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, Efavirenz) drastically reduce Artemether and Lumefantrine levels -> contraindicated! Avoid QTc-prolonging drugs (Quinine, Macrolides, Fluoroquinolones, Ondansetron, Domperidone)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: CRITICAL COUNTER INSTRUCTION: Take your second Day-1 dose exactly 8 hours after the first dose, and take all 6 doses over the 3 days WITH A FULL GLASS OF MILK, CURD, OR FOOD — if taken with plain water on an empty stomach, the medicine is not absorbed and falciparum malaria will come back!
- Meal & Clock Timing Instruction: MANDATORY FAT/MILK ABSORPTION RULE FOR LUMEFANTRINE: Every dose of Artemether + Lumefantrine MUST be taken WITH FOOD OR A GLASS OF MILK! Without dietary fat, Lumefantrine oral absorption drops by 90% and malaria treatment fails! (Day 1: Hour 0 & Hour 8; Days 2 & 3: Morning & Evening (12-hourly) WITH MILK OR FOOD)
- Missed Dose Protocol: If a dose is vomited within 1 hour, repeat immediately with milk; never skip any of the 6 doses
- Geriatric Dispensing Pearl: Monitor ECG (QTc) and potassium in older adults
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.30] (p. 107)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.30]-C73 Artesunate — Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Sever
- [8.31]-C74 Mebendazole — Benzimidazole Beta-Tubulin Polymerisation Inhibitor Anthelmintics
- [8.32]-C75 Diethylcarbamazine Citrate (DEC) — Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine
- [8.29] Chloroquine Phosphate & Primaquine Phosphate — 4-Aminoquinoline Blood Schizonticide & 8-Aminoquinoline Hypnozoit